1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
Delayed Swiss Exchange  -  11:31 2022-08-11 am EDT
584.00 CHF   +2.49%
08/04Merck KGaA profit gets boost from dollar, outweighing higher costs
RE
07/28LONZA : Half-Year Alternative Performance Measures Report
PU
07/25AlphaValue/Baader Europe Lifts Price Target on Lonza, Maintains Add Recommendation
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza : to Expand Inhalation Capabilities at Tampa Site

05/23/2022 | 08:06am EDT
  • Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of continued focus on providing bioavailability enhancement series for global customers
  • Extended services build upon the existing expertise in analytical process development and quality control testing at the Center of Excellence in Bend (US)
  • Expanded development and manufacturing DPI services will be available from June 2022

Basel, Switzerland, 23 May 2022 - Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced it will invest in additional inhalation capabilities. The investment will fund the build-out of an additional inhalation testing capacity at the Tampa (US) site specialized in development, clinical, and commercial manufacturing of small molecule-based therapies targeting respiratory diseases and disorders, such as cancer, asthma, and chronic obstructive pulmonary disease (COPD).

Building upon Lonza's extensive expertise and more than 25 years of experience in supporting particle engineering projects from the Bend (US) site, the expansion will establish additional capacity for dry powder inhaler (DPI) product development services. With a rising global incidence of respiratory illnesses and disorders, the need for improved localized delivery is expected to grow. The extension of the service will provide additional infrastructure to drive efficiency and project delivery for feasibility and early-stage clinical studies.

The increased service capabilities will complement the existing inhalation offering. The new laboratories will be equipped with state-of-the-art analytical equipment and a containment system for highly-potent active pharmaceutical ingredients to provide specialized performance testing, including aerosolized particle analysis. The new laboratories are expected to begin operations in June 2022.

Jeff Williamson, Associate Director Product Development, Small Molecules, Lonza Tampa, commented:"Increasing our capabilities in providing solutions for inhaled products will benefit our existing and future customers. The growth of our Inhalation service network will ensure that our team continues to deliver solutions and support necessary for advancing dry powder inhaler products for pulmonary delivery that often face solubility and bioavailability challenges."Matthew Ferguson, Director, Head of Respiratory Delivery, Lonza Bend, added: "The expansion of the inhalation offering, combined with the extensive experience of the Bend team, will serve to support clinical and commercial projects. The addition of these capabilities in Tampa will provide a seamless offering within the Lonza inhalation network. The offering can also benefit from the customizable Capsugel® Zephyr® inhalation capsule offering".

For more information on Lonza's inhalation services, visit: https://pharma.lonza.com/technologies-products/particle-engineering-inhalation-applications.

Disclaimer

Lonza Group Ltd. published this content on 23 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 May 2022 12:05:00 UTC.


© Publicnow 2022
All news about LONZA GROUP AG
08/04Merck KGaA profit gets boost from dollar, outweighing higher costs
RE
07/28LONZA : Half-Year Alternative Performance Measures Report
PU
07/25AlphaValue/Baader Europe Lifts Price Target on Lonza, Maintains Add Recommendation
MT
07/22TRANSCRIPT : Lonza Group AG, H1 2022 Earnings Call, Jul 22, 2022
CI
07/22Lonza Group Profit Balloons 89% in H1 as Sales Rises 17%
MT
07/22Lonza Confident on 2022 Goals as 1st Half Sales Book Healthy Rise
DJ
07/22Lonza's H1 Attributable Profit Jumps With 17% Sales Growth, Confirms FY22 Outlook
MT
07/22Lonza's first-half core EBITDA gains 16.5%
RE
07/22LONZA : Half-Year Results Report
PU
07/22LONZA : Half-Year Results Presentation
PU
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Financials
Sales 2022 6 209 M 6 603 M 6 603 M
Net income 2022 1 037 M 1 103 M 1 103 M
Net cash 2022 347 M 369 M 369 M
P/E ratio 2022 41,6x
Yield 2022 0,57%
Capitalization 42 273 M 44 940 M 44 953 M
EV / Sales 2022 6,75x
EV / Sales 2023 6,07x
Nbr of Employees 17 154
Free-Float 99,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 569,80 CHF
Average target price 759,13 CHF
Spread / Average Target 33,2%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Maria Soler Nunez Head-Group Operations
Barbara May Richmond Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-25.18%44 940
MODERNA, INC.-31.38%68 174
IQVIA HOLDINGS INC.-15.05%44 704
SEAGEN INC.13.62%32 396
ALNYLAM PHARMACEUTICALS, INC.36.81%27 846
CELLTRION, INC.6.82%22 444